{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:13:25Z","timestamp":1790417605904,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Moyamoya disease and syndrome represent rare entities characterized by progressive stenosis and\/or occlusion of the intracranial blood vessels. We present our series of patients with moyamoya disease and syndrome stratified by underlying disease and analyze differences in presentation and outcome following surgical revascularization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an Institutional Review Board (IRB) approved, retrospective review of all patients surgically revascularized by the senior author (SNM) while at Children\u2019s National Hospital in Washington, DC. Demographic data, presenting symptoms and severity, surgical details, and functional and radiographic outcomes were obtained and analyzed for differences among the underlying cohorts of moyamoya disease and syndrome as well as by unilateral or bilateral disease and index or non-index surgeries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-two patients were identified with the following underlying diseases: six with idiopathic moyamoya disease, six with sickle cell anemia, five with trisomy 21, and five with neurofibromatosis type 1. Thirty hemispheres were revascularized with a significantly reduced rate of stroke from 3.19 strokes\/year (SD\u2009=\u20093.10) to 0.13 strokes\/year (SD\u2009=\u20090.25),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03. When analyzed by underlying cause of moyamoya syndrome, patients with neurofibromatosis type 1 were found to be significantly less likely than the other subtypes of moyamoya syndrome to have had either a clinical stroke (0.0%\u00a0neurofibromatosis type 1 vs. 100.0% sickle cell, 60.0% trisomy 21, or 83.3% moyamoya disease,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) or radiographic stroke (0.0% neurofibromatosis type 1\u00a0vs. 100.0% sickle cell, 60.0% trisomy 21, or 83.3%\u00a0moyamoya disease,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) at time of presentation. Patients with moyamoya syndrome associated with sickle cell disease\u00a0were more likely to present with clinical and radiographic strokes. Additionally, patients with bilateral disease demonstrated no difference in final functional outcome compared to patients with unilateral disease (mRS 0.73 (SD\u2009=\u20091.33) vs. 1.29 (SD\u2009=\u20091.60),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.63).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Indirect surgical revascularization decreases stroke risk for pediatric patients with different forms of moyamoya disease and moyamoya syndrome. Additionally, these data suggest that sickle cell anemia-associated moyamoya syndrome may represent a more aggressive variant, while neurofibromatosis type 1 may represent a more benign variant.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00381-024-06393-w","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T11:01:41Z","timestamp":1715857301000},"page":"2449-2456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of surgical revascularization for pediatric moyamoya disease and syndrome"],"prefix":"10.1007","volume":"40","author":[{"given":"Jason H.","family":"Boulter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Szuflita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh N.","family":"Magge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"6393_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pediatrneurol.2017.01.016","volume":"69","author":"GA DeVeber","year":"2017","unstructured":"DeVeber GA, Kirton A, Booth FA et al (2017) Epidemiology and outcomes of arterial ischemic stroke in children: the Canadian Pediatric Ischemic Stroke Registry. Pediatr Neurol 69:58\u201370","journal-title":"Pediatr Neurol"},{"issue":"23","key":"6393_CR2","doi-asserted-by":"publisher","first-page":"e2479","DOI":"10.1212\/WNL.0000000000009557","volume":"94","author":"MF Rafay","year":"2020","unstructured":"Rafay MF, Shapiro KA, Surmava A-M et al (2020) Spectrum of cerebral arteriopathies in children with arterial ischemic stroke. Neurology 94(23):e2479\u2013e2490","journal-title":"Neurology"},{"issue":"2","key":"6393_CR3","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.3171\/FOC\/2008\/24\/2\/E17","volume":"24","author":"ER Smith","year":"2008","unstructured":"Smith ER, Scott RM (2008) Progression of disease in unilateral moyamoya syndrome. Neurosurg Focus 24(2):E17","journal-title":"Neurosurg Focus"},{"key":"6393_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000093238","volume":"22","author":"ME Kelly","year":"2006","unstructured":"Kelly ME, Bell-Stephens TE, Marks MP, Do HM, Steinberg GK (2006) Progression of unilateral moyamoya disease: a clinical series. Cerebrovasc Dis 22:109\u2013115","journal-title":"Cerebrovasc Dis"},{"issue":"5","key":"6393_CR5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3171\/jns.1996.85.5.0772","volume":"85","author":"K Houkin","year":"1996","unstructured":"Houkin K, Abe H, Yoshimoto T, Takahashi A (1996) Is, \u201cunilateral\u201d moyamoya disease different from moyamoya disease? J Neurosurg 85(5):772\u2013776","journal-title":"J Neurosurg"},{"issue":"6","key":"6393_CR6","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1212\/01.wnl.0000176066.33797.82","volume":"65","author":"K Uchino","year":"2005","unstructured":"Uchino K, Johnson SC, Becker KJ, Tirschwell DL (2005) Moyamoya disease in Washington State and California. Neurology 65(6):956\u2013958","journal-title":"Neurology"},{"issue":"5","key":"6393_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3171\/2018.5.PEDS18163","volume":"22","author":"N Gadgil","year":"2018","unstructured":"Gadgil N, Lam S, Pyarali M, Paldino M, Pan I-W, Dauser RC (2018) Indirect revascularization with the dural inversion technique for pediatric moyamoya disease: 20-year experience. J Neurosurg Pediatr 22(5):541\u2013549","journal-title":"J Neurosurg Pediatr"},{"issue":"1","key":"6393_CR8","first-page":"64","volume":"16","author":"CJ Griessenauer","year":"2015","unstructured":"Griessenauer CJ, Lebensburger JD, Chua MH et al (2015) Encephaloduroarteriosynangiosis and encephalomyoarteriosynagiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg 16(1):64\u201373","journal-title":"J Neurosurg"},{"issue":"6","key":"6393_CR9","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/ajmg.a.38212","volume":"173","author":"C Santoro","year":"2017","unstructured":"Santoro C, Rocco FD, Kossorotoff M et al (2017) Moyamoya syndrome in children with neurofibromatosis type 1: Italian-French experience. Am J Med Genet 173(6):1521\u20131530","journal-title":"Am J Med Genet"},{"issue":"4","key":"6393_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3171\/2012.12.PEDS12281","volume":"11","author":"M Koss","year":"2013","unstructured":"Koss M, Scott RM, Irons MB, Smith ER, Ullrich NJ (2013) Moyamoya syndrome associated with neurofibromatosis type 1: perioperative and long-term outcome after surgical revascularization. J Neurosurg Pediatr 11(4):377\u2013488","journal-title":"J Neurosurg Pediatr"},{"issue":"2","key":"6393_CR11","first-page":"142","volume":"100","author":"RM Scott","year":"2004","unstructured":"Scott RM, Smith JL, Robertson R, Madsen JR, Soriano SG, Rockoff MA (2004) Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg 100(2):142\u2013149","journal-title":"J Neurosurg"},{"issue":"1","key":"6393_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/ana.21981","volume":"68","author":"S-K Kim","year":"2010","unstructured":"Kim S-K, Cho B-K, Phi JH et al (2010) Pediatric moyamoya disease: an analysis of 410 consecutive cases. Ann Neurol 68(1):92\u2013101","journal-title":"Ann Neurol"},{"key":"6393_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.wneu.2019.11.137","volume":"135","author":"S Newman","year":"2020","unstructured":"Newman S, Boulter JH, Malcolm JG, Pradilla I, Pradilla G (2020) Outcomes in patients with moyamoya syndrome and sickle cell disease: a systematic review. World Neurosurgery 135:165\u2013170","journal-title":"World Neurosurgery"},{"issue":"4","key":"6393_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1227\/NEU.0000000000001847","volume":"90","author":"S Newman","year":"2022","unstructured":"Newman S, McMahon JT, Boulter JH, Malcolm JG, Revuelta Barbero JM, Chern JJ, Barrow DL, Pradilla G (2022) Revascularization is associated with a reduced stroke risk in patients with sickle cell-associated moyamoya syndrome. Neurosurgery 90(4):441\u2013446","journal-title":"Neurosurgery"},{"issue":"3","key":"6393_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1586\/ehm.13.25","volume":"6","author":"J Webb","year":"2013","unstructured":"Webb J, Kwiatkowski JL (2013) Stroke in patients with sickle cell disease. Expert Rev Hematol 6(3):301\u2013316","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"6393_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0899-7071(03)00121-9","volume":"28","author":"T Moritani","year":"2004","unstructured":"Moritani T, Numaguchi Y, Lemer NB, Rozans MK, Robinson AE, Hiwatashi A, Westesson PL (2004) Sickle cell cerebrovascular disease: usual and unusual findings on MR imaging and MR angiography. Clin Imaging 28(3):173\u2013186","journal-title":"Clin Imaging"},{"key":"6393_CR17","first-page":"211","volume":"1","author":"TC Hankinson","year":"2008","unstructured":"Hankinson TC, Bohman L-E, Heyer G et al (2008) Surgical treatment of moyamoya syndrome in patients with sickle cell anemia: outcome following encephaloduroarteriosynangiosis. J Neurosurg 1:211\u2013216","journal-title":"J Neurosurg"},{"issue":"1","key":"6393_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/0883073812441059","volume":"28","author":"PS Ghosh","year":"2013","unstructured":"Ghosh PS, Rothner AD, Emch TM, Friedman NR, Moodley M (2013) Cerebral vasculopathy in children with neurofibromatosis type 1. J Child Neurol 28(1):95\u2013101","journal-title":"J Child Neurol"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-024-06393-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-024-06393-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-024-06393-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T06:09:22Z","timestamp":1721801362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-024-06393-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["6393"],"URL":"https:\/\/doi.org\/10.1007\/s00381-024-06393-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1891547\/v1","asserted-by":"object"}]},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"19 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Children\u2019s National Hospital Institutional Review Board without the need for patient consent due to the retrospective and anonymized nature of the data used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No included figures require consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The views expressed in this article are those of the authors and do not reflect the official policy of the Department of Army\/Navy\/Air Force, Department of Defense, or U.S. Government.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}